Equal Pay Day is nothing to celebrate without forward action

Calling for progress

According to the American Association of University Women, women are losing $500 billion each year because of the gender pay gap. Pexels

National Equal Pay Day, which symbolizes how far into the year women must work to earn what men earned in the previous year, falls on April 2 this year and marks a 56-year effort across the nation to have employers address the gender pay gap and provide equal pay for equal work.

That effort is now, closer than ever, to reality as the U.S. House of Representatives, in a heartening move this week, passed the bipartisan Paycheck Fairness Act, authored by Congresswoman Rosa DeLauro and co-sponsored by newly elected Texas Congressman Colin Allred.

The act, among other things, would require employers to prove that pay disparities exist for legitimate job-related reasons, prohibit employers from relying on salary history in determining future pay, provide assistance to all businesses to help them with their equal pay practices and recognize excellence in pay practices by businesses. It would also get rid of rules imposed by employers that prohibit workers from talking about their salary, so women are permitted to ask how much their coworkers are making and find out if they are underpaid.

This legislation is a leap forward in closing the persistent and woeful gender pay.

Statistics show that although more women, nationally, are receiving undergraduate and graduate degrees compared to men, and are equally qualified for the work as their male counterparts, they continue to receive about 82 cents for every dollar earned by men, and women of color earn even less (e.g. Black women earn 63 cents for every dollar and Hispanic women earn just 54 cents for every dollar). At this rate, without any affirmative or proactive changes, it will take another 51 years for women to catch up to men's wages.

In Texas, the outlook around women's pay and the gender gap is grim.

According to the Texas Women's Foundation, in Dallas County, women made almost 93 percent of what men earned, compared to just about 70 percent in Collin County and a little more than 76 percent in Denton County.

According to the American Association of University Women, women are losing $500 billion each year because of the gender pay gap. U.S. corporations suffering those kind of financial losses would send shockwaves through our economic system.

If women made the same pay as men, they would not only be able to better care for their families, but put aside more money in their retirement or pension funds, pay off college loans and mortgages, and enjoy better healthcare and a healthier lifestyle. Research by the Texas Women's Foundation has shown that if working women in Texas were paid the same wages comparable to men, the poverty rate would be reduced by 51 percent.

Companies should not just support the Paycheck Fairness Act, but also become assertive about equal pay and gender diversity, and treat them as an integral part of their business strategy. In order for businesses to truly benefit from the myriad of backgrounds and experiences in our global economy, we must ensure a level-playing field for women and other underrepresented employees. Then and only then will our nation's workplaces and businesses truly thrive. Mr. President and senators — let us pass the Paycheck Fairness Act now.

------

Mandy Price is the CEO and co-founder of Dallas-based Kanarys Inc., a web platform that incorporates data and AI to foster diversity, equity, and inclusion in the workplace.

Just making sure your workplace is diverse isn't enough to solve the problem. Inclusion should be just as important of a goal, says this expert. Getty Images

Data-driven inclusion platform founder says ensuring your workplace is diverse just isn't enough

Guest column

Business leaders have long recognized that a diverse and inclusive workforce results in greater employee engagement, innovation, financial returns and market share. Although the "business case" for diversity has long been proven over the years, and "diversity" has become a buzzword adopted by corporate America, few companies — big or small, new or old — have been able to cultivate real inclusion, acceptance and collaboration in the workplace.

According to a 2018 Atlassian study, State of Diversity and Inclusion in U.S. Tech, less than 30 percent of underrepresented employees feel a sense of belonging in their workplace. By and large, most diversity and inclusion initiatives focus primarily on recruitment and increasing the representation of various demographics in the workforce, with little attention given to inclusion — although research has shown that increases to diversity alone do not improve inclusion.

One reason companies have focused on diversity, as opposed to inclusion, is because it is easy to measure diversity — it is simply a matter of headcount. Traditionally, trying to quantify feelings of inclusion was difficult for organizations to measure. However, it is important to incorporate quantifiable and data-driven strategies to measure inclusion, in order to drive the necessary cultural and structural changes needed in the workplace.

What many companies struggle with, it turns out, is not solving problems, but figuring out what the problems actually are—especially when it comes to creating inclusive workplaces. At Kanarys, we have constructed a unique and robust framework for measuring inclusion, to help companies promote a sense of belonging among their employees in the workplace. Our data-driven approach and methodology relies on artificial intelligence and responsive, anonymous, quantitative surveys, to provide actionable insights in order to promote an environment where all employees feel included and empowered.

Understanding employees' daily lived experiences in the workplace is key and fundamental to understanding an organization's' inclusiveness. However, fear of retaliation and retribution prevents most employees from holding back true and authentic feedback. Benchmarking key aspects of an organization's culture—and understanding the employee experience—is important to understand in order to promote lasting inclusion.

Diversity without inclusion inevitably results in missed opportunities with diverse talent because they no longer feel empowered to contribute and lead. However, if you have both diversity and inclusion, retention and engagement for all employees increases–resulting in a potent mix of innovation, collaboration and success.

Instead of asking "how can we acquire more diverse employees?" we should be asking, "what is it about our systems and culture that prevents us from retaining diverse talent?" Employers must therefore recognize that hiring a few "diverse" employees alone is not enough, and that inclusive cultures don't just happen. They are intentional.

I invite businesses to re-focus their efforts on true diversity, equity, and inclusion and help create workplaces where their employees have a true sense of belonging.

------

Mandy Price is the CEO and co-founder of Dallas-based Kanarys Inc., a web platform that incorporates data and AI to foster diversity, equity, and inclusion in the workplace.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings